Letter to the Editor: The Impact of Adherence and CYP2C19 Phenotype on Escitalopram Exposure in Adolescents

Abstract

Get full access to this article

View all access options for this article.

References

Bousman

, Stevenson

, Ramsey

, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharmacol Ther, 2023; 114(1):51–68; doi: 10.1002/cpt.2903.

Hiemke

, Bergemann

, Clement

, et al. “Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017”: Erratum. Pharmacopsychiatry, 2018; 51(1–2):51; doi: 10.1055/s-0043-116492

Jukić

, Haslemo

, Molden

, et al. Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: A retrospective study based on 2,087 patients. Am J Psychiatry, 2018; 175(5):463–470; doi: 10.1176/appi.ajp.2017.17050550

Strawn

, Mills

, Poweleit

, et al. adverse effects of antidepressant medications and their management in children and adolescents. Pharmacotherapy, 2023; 43(7):675–690; doi: 10.1002/phar.2767

Strawn

, Mills

, Schroeder

, et al. Escitalopram in adolescents with generalized anxiety disorder. J Clin Psychiatry, 2020; 81(5):e1–e9; doi: 10.4088/JCP.20m13396